Interleukin-4 enhances the survival of severe combined immunodeficient mice engrafted with human B-cell precursor leukemia

Blood

Volumn 87, Issue 11, 1996, Pages 4797-4803

  Mitchell, Paul L R ^a   Clutterbuck, Robyn D ^b   Powles, Ray L ^b   De Lord, Corinne ^b   Morilla, Ricardo ^b   Hiorns, Lynne R ^b   Titley, Jennifer ^b   Catovsky, Daniel ^b   Millar, John L ^b  

^a AUSTIN HEALTH   (Australia)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT INTERLEUKIN 4;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; B CELL LEUKEMIA; CANCER INHIBITION; CANCER SURVIVAL; COMBINED IMMUNODEFICIENCY; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0029955153     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v87.11.4797.bloodjournal87114797     Document Type: Article

References (33)

1. Chessells JM, Bailey C, Richards SM: Intensification of treatment and survival in all children with lymphoblastic leukaemia: Results of UK medical research council trial UKALLX. Lancet 345:143, 1995
2. Maggi E, Parronchi P, Manetti R, Simonelli C, Piccinni M-P, Santoni Rugiu F, de Carli M, Ricci M, Romagnani S: Reciprocal regulatory effects of IFNδ and IL4 on the in vitro development of human Th1 and Th2 clones. J Immunol 148:2142, 1992
3. Seder RA, Paul WE, Davis MM, Fazekas de St Groth B: The presence of interleukin 4 during in vitro priming determines the lymphokine-producing potential of CD4+ T cells from T cell receptor transgenic mice. J Exp Med 176:1091, 1992
4. Te Velde AA, Klomp JPG, Yard BA, de Vries JE, Figdor CG: Modulation of phenotypic and functional properties of human peripheral blood monocytes by IL-4. J Immunol 140:1548, 1988
5. 2. Proc Natl Acad Sci USA 86:3803, 1989
6. Defrance T, Vanbervliet B, Aubry J-P, Takebe Y, Arai N, Miyajima A, Yokota T, Lee F, Arai K, de Vries JE, Banchereau J: B cell growth-promoting activity of recombinant human interleukin 4. J Immunol 139:1135, 1987
7. Llorente L, Miljavila F, Crevon M-C, Galanaud P: Dual effects of interleukin 4 on antigen-activated human B cells: Induction of proliferation and inhibition of interleukin 2-dependent differentiation. Eur J Immunol 20:1887, 1990
8. Hofman FM, Brock M, Taylor CR, Lyons B: IL-4 regulates differentiation and proliferation of human precursor B cells. J Immunol 141:1185, 1988
9. 1-positive acute lymphoblastic leukemia cells. Blood 78:1574, 1991
10. Pandrau D, Saeland S, Duvert V, Durand I, Manel A-M, Zabot M-T, Philippe N, Banchereau J: Interleukin 4 inhibits in vitro proliferation of leukemic and normal human B cell precursors. J Clin Invest 90:1697, 1992
11. Manabe A, Coustan-Smith E, Kumagai M, Behm FG, Raimondi SC, Pui C, Campana D: Interleukin-4 induces programmed cell death (apoptosis) in cases of high-risk acute lymphoblastic leukemia. Blood 83:1731, 1994
12. Dorshkind K, Keller GM, Phillips RA, Miller RG, Bosma GC, O'Toole M, Bosma MJ: Functional status of cells from lymphoid and myeloid tissues in mice with severe combined immunodeficiency disease. J Immunol 132:1804, 1984
13. De Lord C, Clutterbuck R, Titley J, Ormerod M, Gordon-Smith T, Millar J, Powles R: Growth of primary human acute leukemia in severe combined immunodeficient mice. Exp Hematol 19:991, 1991
14. De Lord C, Clutterbuck R, Powles R, Morilla R, Hanby A, Titley J, Min T, Millar J: Growth of primary human acute lymphoblastic and myeloblastic leukemia in SCID mice. Leuk Lymphoma 16:157, 1994
15. Kamel-Reid S, Letarte M, Doedens M, Greaves A, Murdoch B, Grunberger T, Lapidot T, Thorner P, Freedman MH, Phillips RA, Dick JE: Bone marrow from children in relapse with pre-B acute lymphoblastic leukemia proliferates and disseminates rapidly in scid mice. Blood 78:2973, 1991
16. Uckun FM, Sather H, Reaman G, Shuster J, Land V, Trigg M, Gunther R, Chelstrom L, Bleyer A, Gaynon P, Crist W: Leukemic cell growth in SCID mice as a predictor of relapse in high-risk B-lineage acute lymphoblastic leukemia. Blood 85:873, 1995
17. Greaves MF: Differentiation-linked leukemogenesis in lymphocytes. Science 234:697, 1986
18. De Lord C, Clutterbuck RD, Powles RL, Min T, Titley JC, Millar JL: Human Philadelphia chromosome-positive chronic myeloid leukemia: A potential model for antisense therapy. Exp Hematol 21:826, 1993
19. Mitchell P, Clutterbuck R, Powles R, De Lord C, Titley J, Millar J: Human leukaemias engrafted into SCID mice - A model for in vivo testing of cytotoxic therapy. Blood 84:622a, 1994 (abstr, suppl 1)
20. Touw I, Pouwels K, van Agthoven T, van Gurp R, Budel L, Hoogerbrugge H, Delwel R, Goodwin R, Namen A, Lowenberg B: Interleukin-7 is a growth factor of precursor B and T acute lymphoblastic leukemia. Blood 75:2097, 1990
21. Skjonsberg C, Erikstein BK, Smeland EB, Lie SO, Funderud S, Beiske K, Blomhoff HK: Interleukin-7 differentiates a subgroup of acute lymphoblastic leukemias. Blood 77:2445, 1991
22. Bosco M, Giovarelli M, Forni M, Modesti A, Scarpa S, Masuelli L, Forni G: Low doses of IL-4 injected perilymphatically in tumor-bearing mice inhibit the growth of poorly and apparently nonimmunogenic tumors and induce a tumor-specific immune memory. J Immunol 145:3136, 1990
23. Tepper RI, Pattengale PK, Leder P: Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell 57:503, 1989
24. Golumbek PT, Lazenby AJ, Levitsky HI, Jaffee LM, Karasuyama H, Baker M, Pardoll DM: Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 254:713, 1991
25. Mosmann TR, Yokota T, Kastelein R, Zurawski SM, Arai N, Takebe Y: Species-specificity of T cell stimulating activities of IL 2 and BSF-1 (IL 4): Comparison of normal and recombinant, mouse and human IL 2 and BSF-1 (IL 4). J Immunol 138:1813, 1987
26. Toi M, Bicknell R, Harris AL: Inhibition of colon and breast carcinoma cell growth by interleukin-4. Cancer Res 52:275, 1992
27. Puri RK, Siegel JP: Interleukin-4 and cancer therapy. Cancer Invest 11:473, 1993
28. Gilleece MH, Scarffe JH, Ghosh A, Heyworth CM, Bonnem E, Testa N, Stern P, Dexter TM: Recombinant human interleukin 4 (IL-4) given as daily subcutaneous injections - A phase I dose toxicity trial. Br J Cancer 66:204, 1992
29. Atkins MB, Vachino G, Tilg HJ, Karp DD, Robert NJ, Kappler K, Mier JW: Phase I evaluation of thrice-daily intravenous bolus interleukin-4 in patients with refractory malignancy. J Clin Oncol 10:1802, 1992
30. Prendiville J, Thatcher N, Lind M, McIntosh R, Ghosh A, Stern P, Crowther D: Recombinant human interleukin-4 (rhuIL-4) administered by the intravenous and subcutaneous routes in patients with advanced cancer - A phase I toxicity study and pharmacokinetic analysis. Eur J Cancer 29A:1700, 1993
31. Margolin K, Aronson FR, Sznol M, Atkins MB, Gucalp R, Fisher RI, Sunderland M, Doroshow JH, Ernest ML, Mier JW, Dutcher JP, Gaynor ER, Weiss GR: Phase II studies of recombinant human interleukin-4 in advanced renal cancer and malignant melanoma. J Immunother 15:147, 1994
32. Sosman JA, Fisher SG, Kefer C, Fisher RI, Ellis TM: A phase 1 trial of continuous infusion interleukin-4 (IL-4) alone and following interleukin-2 (IL-2) in cancer patients. Ann Oncol 5:447, 1994
33. Davis I, Maher D, Cebon J, Dyer W, McKendrick J, Begley G, Woodruff R, Green M, Fox R, Rallings M, Bonnem E, Boyd A, Mortsyn G: Pharmacokinetic and clinical studies of interleukin-4 (IL-4) in patients with malignancy. Proc ASCO 10:287, 1991 (abstr)